Do you modify your choice of systemic therapy for localized early stage ER+/PR+ HER2- breast if Mammaprint shows basal subtype?

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

Answer from: Medical Oncologist at Academic Institution

It would make me want to recheck the ER/PR IHC through another lab to make sure it is truly positive. There are some ER positive tumors (especially low expressors) that have basal transcriptional profiles suggesting a lack of estrogen pathway signaling. If the ER is truly positive and it is >= 10...

Comments

Medical Oncologist at Geisinger Medical Center
Do you gave a cutoff on the ER/PR% to decide when ...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
ASCO/CAP 2020 guidelines use the 1-9% ER definitio...

Medical Oncologist at NYU Winthrop Hospital
ER, less than 1% is ER-negative. Anything above 1...

Answer from: Medical Oncologist at Community Practice

I think the first thing to make sure if we are using Mammaprint to guide chemotherapy is: Was it sent in a clinically high risk tumor? Was the Mammaprint high or low risk? Assuming the Mammaprint was low risk for a clinically high risk tumor, I do not believe we have data to use the basal sub...

Related Questions